+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Incidence and consistency of antiretroviral use among HIV-infected medicaid beneficiaries with schizophrenia

Incidence and consistency of antiretroviral use among HIV-infected medicaid beneficiaries with schizophrenia

Journal of Clinical Psychiatry 62(3): 174-178

Objective: To investigate the incidence and consistency of antiretroviral (ARV) treatment in the period before the introduction of protease inhibitors among Medicaid beneficiaries in New Jersey who had both the human immunodeficiency virus (HIV) and schizophrenia. Method: HIV-infected Medicaid beneficiaries were identified using the HIV and acquired immunodeficiency syndrome (AIDS) registries for New Jersey; claims histories were used to identify patients diagnosed with ICD-9-CM schizophrenia and affective psychoses and to examine use of ARV drugs. Results: Bivariate and multivariate analysis found no difference in the likelihood of receiving ARV drugs between patients with HIV and schizophrenia and HIV-infected patients without schizophrenia. However, once the therapy was initiated, patients with schizophrenia were more consistent users of ARV drugs. Conclusion: Results do not indicate that HIV-seropositive (HIV+) patients with schizophrenia are less adherent to HIV therapies than HIV+ patients without schizophrenia. In our study population, consistency of use was actually higher among HIV+ patients with schizophrenia, perhaps because their multiple diagnoses place them under closer medical scrutiny.

(PDF emailed within 1 workday: $29.90)

Accession: 010819826

Download citation: RISBibTeXText

PMID: 11305703

Related references

Use of newer antiretroviral treatments among HIV-infected medicaid beneficiaries with serious mental illness. Journal of Clinical Psychiatry 65(9): 1180-1189, 2004

Potential adult Medicaid beneficiaries under the Patient Protection and Affordable Care Act compared with current adult Medicaid beneficiaries. Annals of Family Medicine 11(5): 406-411, 2014

Assisted living and use of health services among medicaid beneficiaries with schizophrenia. Journal of Mental Health Policy and Economics 6(2): 59-65, 2003

Medication continuity among Medicaid beneficiaries with schizophrenia and bipolar disorder. Psychiatric Services 64(9): 878-885, 2014

The impact of managed care on access to highly active antiretroviral therapy and on outcomes among Medicaid beneficiaries with AIDS. Medical Care Research and Review 64(1): 66-82, 2007

Outcomes for Medicaid beneficiaries with schizophrenia under a prepaid mental health carve-out. Journal of Behavioral Health Services & Research 26(4): 442-450, 1999

State and demographic variation in use of depot antipsychotics by Medicaid beneficiaries with schizophrenia. Psychiatric Services 65(1): 121-124, 2014

Outcomes of medicaid beneficiaries with schizophrenia receiving clozapine only or antipsychotic combinations. Psychiatric Services 66(2): 127-133, 2015

Use of Medicaid data to explore community characteristics associated with HIV prevalence among beneficiaries with schizophrenia. Public Health Reports 126 Suppl 3(): 89-101, 2011

Prevalence of diagnosed HIV disease among medicaid beneficiaries with schizophrenia in U.S. metropolitan areas. Journal of Nervous and Mental Disease 198(9): 682-686, 2010

Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. American Journal of Psychiatry 161(4): 692-699, 2004

State Variation in the Delivery of Comprehensive Services for Medicaid Beneficiaries with Schizophrenia and Bipolar Disorder. Community Mental Health Journal 51(5): 523-534, 2016

Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatric Services 58(7): 1007-1010, 2007

Emergency department utilization among Medicaid beneficiaries with schizophrenia and diabetes: the consequences of increasing medical complexity. Schizophrenia Research 152(2-3): 490-497, 2014

The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia. Administration and Policy in Mental Health 34(3): 307-314, 2007